Results 111 to 120 of about 260,498 (362)

Interactions in vivo between the Vif protein of HIV-1 and the precursor (Pr55GAG) of the virion nucleocapsid proteins [PDF]

, 2009
The abnormality of viral core structure seen in vif-defective HIV-1 grown in PBMCs has suggested a role for Vif in viral morphogenesis. Using an in vivo mammalian two-hybrid assay, the interaction between Vif and the precursor (Pr55GAG) of the virion ...
A Harmache, A Mehle, AM Borman, AM Sheehy, AM Sheehy, B Liu, B Liu, B Mangeat, C Tian, DH Gabuzda, DH Gabuzda, Farhatullah Syed, H Ochman, H Zhang, HA Vasavada, I Sadowski, JH Simon, K Luo, K Stopak, L Baraz, L Fan, M Bouyac, M Bouyac, M Boyce, M Marin, MA Adekale, Malcolm A. McCrae, MS Oberste, N Madani, RA Fouchier, RC Desrosiers, RS Harris, S Cen, S Erickson-Viitanen, S Hoglund, SG Conticello, SK Arya, TH Lee, X Yu, Y Gluzman, Y Imai, Y Yu, YH Zheng   +42 more
core   +1 more source

HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites

Open Medicinal Chemistry Journal, 2011
The impact of highly active antiretroviral therapy (HAART) in the natural history of AIDS disease has been allowed to prolong the survival of people with HIV infection, particularly whose with increased HIV viral load.
Y. Alfonso, L. Monzote
semanticscholar   +1 more source

CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target

Advanced Science, EarlyView.
This review conceptualizes CD147 as a fundamental “Energy‐Structure Coupler,” physically bridging metabolic flux (via MCTs) with morphogenetic plasticity (via integrins/MMPs) to drive cancer, infection, and autoimmunity. Addressing the “specificity paradox” that limits current translation, the authors chart a strategic roadmap—spanning logic‐gated ...
Xiang‐Min Yang, Huijie Bian, Zhi‐Nan Chen   +2 more
wiley   +1 more source

Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1 [PDF]

, 2007
With ongoing generation of viral genetic diversity and increasing levels of migration, the global human immunodeficiency virus type 1 (HIV-1) epidemic is becoming increasingly heterogeneous.
, de Oliveira, Tulio, Dunn, David, Gifford, Robert J., Kellam, Paul, Pillay, Deenan, Pybus, Oliver G., Rambaut, Andrew, Vandamme, Anne-Mieke   +8 more
core   +2 more sources

Disrupting Lipid Raft Microdomains to Block Polyploid Giant Cancer Cell Budding and Enhance Radiotherapy Response

Advanced Science, EarlyView.
Radiation induces polyploid giant cancer cells (PGCCs) that regenerate tumors through virus‐like budding. This process depends on a SNCG–FLOT2–CHMP4B signaling axis functioning in lipid raft microdomains. Disrupting these domains using statins or anti‐PCSK9 antibodies blocks PGCC budding, suppresses tumor repopulation, and enhances radiotherapy ...
Zheng Deng, Haoran Sun, Jin Cheng, Ruyi Zhao, Jianzhu Xie, Yanwei Song, Yucui Zhao, Chenwei Lin, Binjie Hu, Yanping Gong, Jun Lin, Sijia He, Yuntao Luo, Minghui Zhao, Yiwei Wang, Ming Jiao, Yuqin Yang, Jikun Li, Shujie Xia, Chuanyuan Li, Qian Huang   +20 more
wiley   +1 more source

Drogas anti-VIH: passado, presente e perspectivas futuras Drugs anti-HIV: past, present and future perspectives

Química Nova, 2003
Currently available anti-HIV drugs can be classified into three categories: nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs).
Marcus Vinícius Nora de Souza, Mauro Vieira de Almeida   +1 more
doaj   +1 more source

Antibody‐Empowered Nanomedicine for Precise Biomedical Applications

Advanced Science, EarlyView.
This review explores strategies for functionalizing nanoparticles with antibodies to construct antibody‐empowered nanomedicine. It discusses the classification of these nanomedicines based on antibody structure, with a specific focus on their biomedical applications in diagnostics, bioimaging, and therapeutics for various diseases.
Chen Chen, Xinglin Chen, Zhenhao Gao, Meng Sun, Yaozong Yu, Fang Lv, Qiujun Wang, Jinfeng Zhang   +7 more
wiley   +1 more source

Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs

Molecules, 2019
HIV protease inhibitors against the viral protease are often hampered by drug resistance mutations in protease and in the viral substrate Gag. To overcome this drug resistance and inhibit viral maturation, targeting Gag alongside protease rather than ...
Chinh Tran-To Su, Darius Wen-Shuo Koh, Samuel Ken-En Gan   +2 more
doaj   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Specific HIV Protease Inhibitors Inhibit the Ability of Hpv16 E6 to Degrade P53 and Selectively Kill E6-Dependent Cervical Carcinoma Cells In Vitro [PDF]

, 2006
Lynne Hampson, Henry C Kitchener, Ian Hampson   +2 more
openalex   +1 more source